Investors

Genomic Health, Inc. (NASDAQ: GHDX) is a global cancer company focused on the development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions.

PDF Genomic Health Corporate Presentation (May 10, 2013)

View all »   RSSRecent Press Releases

May 21, 2013
Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting

May 10, 2013
Genomic Health Announces Medicare Expanded Coverage Policy for Oncotype DX® Breast Cancer Test to Include Ductal Carcinoma in Situ (DCIS) Diagnosis

View all »Webcasts & Presentations

May 14, 2013 at 5:00 PM ET
Genomic Health to Present at Bank of America Merrill Lynch Health Care Conference

May 10, 2013
Genomic Health Corporate Presentation

May 8, 2013 at 1:00 PM PT
Webcast to Review Positive Clinical Validation and Development of the Oncotype DX® Prostate Cancer Test

May 2, 2013 at 1:30 PM PT
Genomic Health First Quarter 2013 Financial Results Webcast

DISCLAIMER

The information in the fact sheet, press releases and webcasts should be considered accurate only as of the date of the document or presentation. We disclaim any obligation to supplement or update the information in these documents or presentations.

Forward-Looking Statements

This website contains forward-looking statements. Any statements contained in this website that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will," "intends" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including risks and uncertainties associated with the reimbursement for and adoption of Oncotype DX; commercialization of any future tests; the nature and sources of our revenues; our dependence on collaborative relationships; the regulation of Oncotype DX or any future tests we may develop by the FDA; the attributes of our products; the benefits of personalized medicine and its ability to impact treatment decisions; the outcome and success of clinical trials; the applicability of clinical results to actual outcomes; the company's beliefs regarding the potential benefits that may be obtained from additional tests; and other factors detailed from time to time in Genomic Health's periodic filings with the Securities and Exchange Commission. Genomic Health, Inc. specifically disclaims any obligation to update any forward-looking statements.

Contact Information

For Investors:
650.569.2281
investors@genomichealth.com

For Media:
650.569.2215
media@genomichealth.com

Email Alerts

To sign-up to receive email alerts for press releases, stock information, new calendar events and/or SEC filings click here.

Shareholder Tools